Structured intelligence coverage

Structured records are temporarily unavailable. The published profile and its source ledger remain accessible.

Identity checks do not refresh the age of governance evidence. Open a record for its source date and review state.

Profile

Identity, professional record and current appointments.

Overview

Professional record at a glance

A concise summary of information supported by the cited public sources. Missing information is treated as unknown, not as a negative finding.

Current roles
11 current organization shown on this profile
Board positions
11 supported by public sources, 0 supplied by the profile owner
Committee roles
1Roles supported by the sources cited on this profile
Qualifications
Not establishedNo qualification is currently confirmed by the cited sources

Professional narrative

About

Mr. Mahatme has served on the CRISPR Therapeutics Board since May 2024 and is currently CEO and Chief Business Officer of Vor Biopharma. He previously served as President, COO and CFO of National Resilience Inc. and as EVP, CFO and Chief Business Officer of Sarepta Therapeutics. He holds Master of Laws degrees from Cornell Law School and New York University School of Law.

Sources are shown with the information they support.

Current roles

Appointments & responsibilities

Board appointments

Governance

Board appointments, committee responsibilities and disclosed relationships.

Committee appointments across companies · Temporarily unavailable

Structured records for this section are unavailable. This does not establish that no records exist. Published profile sources remain in Evidence & History.

Board and advisory record

Board service

Sources are shown with each role, education record, or credential.

Director

CRISPR Therapeutics AG

2024-01-01 · current

Confirmed by public sourceView source

Connections

Explore the roles, education and affiliations published in this record.

CRISPR Therapeutics AG

Open CRISPR Therapeutics AG profile →

Director at CRISPR Therapeutics AG

2024-01-01 → End not stated

current · source reported

Observed: 2026-09-25

CRISPR Therapeutic…CRISPR Therapeutics AGSandesh Mahatme, L…

Dashed lines mark past roles. Select a connection to see its dates and sources.

Relationship map

Connected through the public record

Direct relationships from verified facts and published résumé records. Private connections are excluded.

Direct public links only

Only published affiliations are shown here. Private relationships require authorized access.

Experience

Career history, education, credentials and public contributions.

Published record

Featured coverage

Selected publications and public sources used to establish this profile. Inclusion records provenance; it is not an endorsement.

Source 1 · Sec FilingCRSP DEF 14A director slateSupports AI and ML experience, Board role, Committee assignments, Executive company, Executive title, Cybersecurity experience, Technology background.Open source

Basis

Identifiers, sources, dates and record limitations.

Identifiers

Alpha ID
alpha:person:sandesh-mahatme-ll-m
Record version
public-0

Published evidence records

3 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. CRSP DEF 14A director slate

    sec filing · Source published: Apr 21, 2026 · Retrieved: May 6, 2026

    Supports 7 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 6, 2026
    • Board role: Board role: Director · Claim reviewed: May 6, 2026
    • Committee assignments: Committee assignments: Audit · Claim reviewed: May 6, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 6, 2026
    • Executive company: Executive at Vor Biopharma, Inc. · Claim reviewed: May 6, 2026
    • Executive title: Executive title: Chief Executive Officer and Chief Business Officer · Claim reviewed: May 6, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 6, 2026

  2. Open source

    sec proxy · Source published: Apr 21, 2026 · Retrieved: May 3, 2026

    Supports 1 claim
    • Professional Role: Director at CRISPR Therapeutics AG · Claim reviewed: May 6, 2026

  3. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of CRISPR Therapeutics AG · Claim reviewed: May 6, 2026

Sources

Sources and published information

Each item links to the public source used to support it. When sources disagree, the item is clearly marked for review.

AI and ML experience · Source reportedAI and ML experience: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 6, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 6, 2026

Board membership · Source reportedServes on the board of CRISPR Therapeutics AG1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Board role · Source reportedBoard role: Director1 source
Verification
Source reported
Confidence
92%
Last reviewed
May 6, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 6, 2026

Committee assignments · Source reportedCommittee assignments: Audit1 source
Verification
Source reported
Confidence
88%
Last reviewed
May 6, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 6, 2026

Cybersecurity experience · Source reportedCybersecurity experience: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 6, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 6, 2026

Executive company · Source reportedExecutive at Vor Biopharma, Inc.1 source
Verification
Source reported
Confidence
85%
Last reviewed
May 6, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 6, 2026

Executive title · Source reportedExecutive title: Chief Executive Officer and Chief Business Officer1 source
Verification
Source reported
Confidence
85%
Last reviewed
May 6, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 6, 2026

Technology background · Source reportedTechnology background: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 6, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 6, 2026

View all sources3 records
  1. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 6, 2026

    Supports: AI and ML experience · Board role · Committee assignments · Executive company · Executive title · Cybersecurity experience · Technology background

  2. https://www.sec.gov/Archives/edgar/data/1674416/000119312526165158/crsp-20260421.htm

    Sec Proxy · Tier not stated · Reviewed May 3, 2026

    Supports: Director at CRISPR Therapeutics AG (NASDAQ: CRSP)

  3. https://www.sec.gov/Archives/edgar/data/1674416/000119312526165158/crsp-20260421.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership